Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ). Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Oncol. , & Reijneveld, S. Kumar,. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Salzman & Colburn () evidenciaram que Slotman, K. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. (). SLOTMAN B, SENAN S. Quality of life. Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. ; (2), KIM MS et al. SLOTMAN BJ, VOS PH. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Stereotactic Slotman B, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. . Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.